DMK Pharmaceuticals Corporation Common Stock
DMK was delisted on the 6th of February, 2024.
46 hedge funds and large institutions have $29M invested in DMK Pharmaceuticals Corporation Common Stock in 2017 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 17 increasing their positions, 14 reducing their positions, and 6 closing their positions.
587% more call options, than puts
Call options by funds: $6.55M | Put options by funds: $953K
75% more capital invested
Capital invested by funds: $16.5M → $29M (+$12.5M)
50% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 6
21% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 14
5% more funds holding
Funds holding: 44 → 46 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
+$9.19M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.48M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$1.01M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$958K |
| 5 |
EI
EAM Investors
Solana Beach,
California
|
+$694K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$2.08M |
| 2 |
SGS
Sterling Global Strategies
Carlsbad,
California
|
-$286K |
| 3 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
-$260K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$170K |
| 5 |
IA
IFP Advisors
Tampa,
Florida
|
-$167K |
DMK Hedge Fund Activity: Q3 2017 in Review
46 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in DMK Pharmaceuticals Corporation Common Stock (DMK) for Q3 2017, worth a combined $29M — up 75% from $16.5M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new DMK positions and 6 closed out — a net gain of 3 holders — while 17 added to existing stakes and 14 trimmed.
The largest buyer was Sio Capital Management, adding an estimated $9.19M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $2.08M sold.
- 46 institutional investors held DMK Pharmaceuticals Corporation Common Stock (DMK) as of Q3 2017, up from 44 in Q2 2017.
- Funds reported $29M of DMK Pharmaceuticals Corporation Common Stock stock for Q3 2017, up 75% quarter-over-quarter.
- 9 funds opened new DMK Pharmaceuticals Corporation Common Stock positions in Q3 2017 and 6 closed out, a net change of +3 holders.
- The largest DMK Pharmaceuticals Corporation Common Stock buyer in Q3 2017 was Sio Capital Management, an estimated $9.19M added.
- The largest DMK Pharmaceuticals Corporation Common Stock seller in Q3 2017 was Perceptive Advisors, an estimated $2.08M sold.
Based on aggregated 13F filings for Q3 2017.